Gregory Robbins | Associate Director, Labs, Flow Cytometry
The PPD clinical research business of Thermo Fisher Scientific

Gregory R. Robbins, Ph.D. is a molecular and cellular immunologist with more than 15 years’ experience spanning academic research and life sciences industry leadership. He earned his Ph.D. in microbiology and immunology from Loyola University Chicago, where his research focused on B cell development and antibody diversification. During his postdoctoral training at the University of North Carolina at Chapel Hill in the laboratories of Jenny Ting and Joseph DeSimone, he investigated innate immune responses to nanoparticle-based vaccine platforms and contributed to foundational work on pulmonary and mucosal vaccine delivery systems, including first-author publications in PNAS, Nanomedicine, and the Journal of Immunology. Dr. Robbins has played a key role in advancing translational vaccine technologies, including the development of 3D-printed and dissolvable microneedle delivery systems and engineered nanoparticle platforms designed to modulate immune responses. His work has resulted in multiple patents in additive manufacturing and biomedical device innovation. In industry, he has led multidisciplinary R&D teams, directed product development initiatives, and overseen validation strategies for regulated biomedical products, materials science, and scalable manufacturing. Through his combined expertise in immune profiling, vaccine delivery technologies, and product commercialization, he brings a uniquely integrated perspective to vaccine innovation — from mechanistic immunology to engineered delivery platforms and real-world implementation.